Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Adult
Aged
Aged, 80 and over
Amides
/ therapeutic use
Antiviral Agents
/ therapeutic use
COVID-19
/ epidemiology
Chloroquine
/ therapeutic use
Darunavir
/ therapeutic use
Disease Progression
Drug Combinations
Female
Hospitals
Hospitals, University
Humans
Hydroxychloroquine
/ therapeutic use
Lopinavir
/ therapeutic use
Male
Middle Aged
Pyrazines
/ therapeutic use
Referral and Consultation
Retrospective Studies
Ritonavir
/ therapeutic use
Thailand
/ epidemiology
Treatment Outcome
Young Adult
COVID-19 Drug Treatment
COVID-19
Clinical characteristics
Epidemiology
Outcome
Thailand
Treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
received:
15
07
2020
accepted:
15
04
2021
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
29
4
2021
Statut:
epublish
Résumé
The epidemiology and outcomes of COVID-19 patients in Thailand are scarce. This retrospective cohort study included adult hospitalized patients who were diagnosed with COVID-19 at Siriraj Hospital during February 2020 to April 2020. The prevalence of COVID-19 was 7.5% (107 COVID-19 patients) among 1409 patients who underwent RT-PCR for SARS-CoV-2 detection at our hospital during the outbreak period. Patients with COVID-19 presented with symptoms in 94.4%. Among the 104 patients who were treated with antiviral medications, 78 (75%) received 2-drug regimen (lopinavir/ritonavir or darunavir/ritonavir plus chloroquine or hydroxychloroquine), and 26 (25%) received a 3-drug regimen with favipiravir added to the 2-drug regimen. Disease progression was observed in 18 patients (16.8%). All patients with COVID-19 were discharged alive. The prevalence of COVID-19 was 7.5% among patients who underwent RT-PCR testing, and 10% among those having risk factors for COVID-19 acquisition. Combination antiviral therapies for COVID-19 patients were well-tolerated and produced a favorable outcome.
Sections du résumé
BACKGROUND
BACKGROUND
The epidemiology and outcomes of COVID-19 patients in Thailand are scarce.
METHODS
METHODS
This retrospective cohort study included adult hospitalized patients who were diagnosed with COVID-19 at Siriraj Hospital during February 2020 to April 2020.
RESULTS
RESULTS
The prevalence of COVID-19 was 7.5% (107 COVID-19 patients) among 1409 patients who underwent RT-PCR for SARS-CoV-2 detection at our hospital during the outbreak period. Patients with COVID-19 presented with symptoms in 94.4%. Among the 104 patients who were treated with antiviral medications, 78 (75%) received 2-drug regimen (lopinavir/ritonavir or darunavir/ritonavir plus chloroquine or hydroxychloroquine), and 26 (25%) received a 3-drug regimen with favipiravir added to the 2-drug regimen. Disease progression was observed in 18 patients (16.8%). All patients with COVID-19 were discharged alive.
CONCLUSIONS
CONCLUSIONS
The prevalence of COVID-19 was 7.5% among patients who underwent RT-PCR testing, and 10% among those having risk factors for COVID-19 acquisition. Combination antiviral therapies for COVID-19 patients were well-tolerated and produced a favorable outcome.
Identifiants
pubmed: 33902480
doi: 10.1186/s12879-021-06081-z
pii: 10.1186/s12879-021-06081-z
pmc: PMC8072093
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Drug Combinations
0
Pyrazines
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Chloroquine
886U3H6UFF
favipiravir
EW5GL2X7E0
Ritonavir
O3J8G9O825
Darunavir
YO603Y8113
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
382Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Infection. 2020 Oct;48(5):687-694
pubmed: 32390091
Euro Surveill. 2020 Feb;25(8):
pubmed: 32127124
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32364890
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Emerg Infect Dis. 2020 Jul;26(7):1580-1585
pubmed: 32267826
N Engl J Med. 2020 Mar 12;382(11):1067-1068
pubmed: 32050060
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Am J Trop Med Hyg. 2020 May;102(5):940-942
pubmed: 32238223
JAMA. 2020 May 19;323(19):1966-1967
pubmed: 32232421
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041
pubmed: 32936252
Clin Microbiol Infect. 2020 Jul;26(7):842-847
pubmed: 32344166